Chester County News and Community Website
NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) said its experimental lung cancer drug firmonertinib failed to significantly improve progression-free survival compared with chemotherapy in a pivotal Phase 3 …
ArriVent’s Lung Cancer Drug Fails Key Phase 3 Trial Endpoint Read More
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) reported that its liver disease drug Rezdiffra improved measures of liver damage across patients carrying common genetic risk variants for metabolic dysfunction-associated …
Madrigal Study Finds Rezdiffra Benefits Across Genetic Risks Read More
BLUE BELL, PA — inTRAvent Medical Partners LP has completed the first patient procedure using its SOLOPASS 2.0 ultrasound-guided neuronavigation system in a clinical trial at Penn State Health Milton …
inTRAvent Begins Human Trial of Brain Catheter Navigation System Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration is seeking public input on safety requirements and clinical trial designs for ibogaine, a psychedelic compound being investigated for opioid use …
FDA Seeks Input on Ibogaine Trials Amid Safety Concerns Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that its oral psoriasis treatment ICOTYDE (icotrokinra) maintained skin clearance through 112 weeks in a Phase 3 clinical study, providing …
Johnson & Johnson Psoriasis Drug Sustains Clearance at Two Years Read More
CONSHOHOCKEN, PA — Suvoda is expanding artificial intelligence and integrated workflow capabilities across its clinical-trial technology platform, reporting that its agentic randomization and trial-supply technology can reduce study setup timelines …
Suvoda Uses AI to Cut Clinical-Trial Setup Times Read More
WASHINGTON, D.C. — The Department of Health and Human Services is backing a new clinical-trial model that would use predictive simulations, real-time statistical analysis and automation to reduce the time, …
HHS Targets Clinical Trial Costs With Adaptive Trial Push Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that adolescents with generalized myasthenia gravis maintained improvements in daily function and muscle strength through two years of IMAAVY treatment, …
J&J’s IMAAVY Maintains Gains in Two-Year Adolescent Study Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) will present Phase 3 data this month examining whether its experimental hypertension drug lorundrostat reduced both blood pressure and albuminuria in patients …
Mineralys Extends Lorundrostat Focus to Kidney Disease Read More
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) remains on track to seek U.S. clearance in the fourth quarter to begin clinical testing of CNTY-813, its experimental type 1 diabetes …
Century Advances Diabetes Cell Therapy Toward FDA Filing Read More